文献速递乳腺癌

优化三阴性乳腺癌一线分子亚型导向治疗(FUTURE-SUPER):多队列随机2期试验

Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2024-01-08

FUTURE-SUPER是在中国复旦大学附属肿瘤医院开展的多队列随机2期试验,将139例初治转移或复发性三阴性乳腺癌患者按分子亚型及基因组标志物分5个队列,1:1随机接受白蛋白紫杉醇单药(对照组70例)或联合亚型导向方案(亚型导向组69例)。中位随访22.5个月,亚型导向组中位无进展生存期11.3个月(95%CI 8.6-15.2)显著长于对照组5.8个月(4.0-6.7),HR 0.44(95%CI 0.30-0.65),p<0.0001。

要点

  • 亚型导向组中位无进展生存期11.3个月,对照组5.8个月,HR 0.44(95%CI 0.30-0.65),p<0.0001。
  • 3-4级治疗相关不良事件最常见为中性粒细胞减少:亚型导向组21/69(30%)vs 对照组16/70(23%)。
  • 治疗相关严重不良事件:亚型导向组7/69(10%),对照组0例;两组均无治疗相关死亡。

核心结论

  • 研究结果提示分子亚型导向治疗优化在三阴性乳腺癌患者中具有潜在临床获益,提示了进一步临床研究的方向。

研究设计与样本

  • FUTURE-SUPER为正在进行的开放标签、随机、对照2期试验,在中国上海复旦大学附属肿瘤医院开展。
  • 纳入18-70岁女性,ECOG体能状态0-1,组织学确诊的未经治疗转移或复发性三阴性乳腺癌。
  • 将参与者按分子亚型和基因组生物标志物分为5个队列,按亚型分层以区组大小4按1:1随机分组。
  • 对照组接受白蛋白紫杉醇(100 mg/m2,静脉给药,第1、8、15天),28天为一周期。
  • 亚型导向组在相同白蛋白紫杉醇基础上按亚型加用相应方案:LAR-HER2mut用吡咯替尼400 mg口服每日;LAR-PI3K/AKTmut和MES-PI3K/AKTmut用依维莫司10 mg口服每日;免疫调节型用卡瑞利珠单抗200 mg静脉给药第1、15天联合法米替尼20 mg口服每日;BLIS/MES-PI3K/AKTWT用贝伐珠单抗10 mg/kg静脉给药第1、15天。

主要发现

  • 2020年7月28日至2022年10月16日共入组139例女性参与者,亚型导向组69例,对照组70例。
  • 数据截止2023年5月31日,中位随访22.5个月(IQR 15.2-29.0)。
  • 亚型导向组中位无进展生存期11.3个月(95%CI 8.6-15.2),对照组5.8个月(4.0-6.7),HR 0.44(95%CI 0.30-0.65),p<0.0001。
  • 3-4级治疗相关不良事件:中性粒细胞减少亚型导向组21/69(30%)vs对照组16/70(23%);贫血亚型导向组5/69(7%)vs对照组0/70;丙氨酸氨基转移酶升高亚型导向组4/69(6%)vs对照组1/70(1%)。
  • 治疗相关严重不良事件:亚型导向组7/69(10%),对照组0/70;两组均未报告治疗相关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple-negative breast cancers display heterogeneity in molecular drivers and immune traits. We previously classified triple-negative breast cancers into four subtypes: luminal androgen receptor (LAR), immunomodulatory, basal-like immune-suppressed (BLIS), and mesenchymal-like (MES). Here, we aimed to evaluate the efficacy and safety of subtyping-based therapy in the first-line treatment of triple-negative breast cancer. METHODS: FUTURE-SUPER is an ongoing, open-label, randomised, controlled phase 2 trial being conducted at Fudan University Shanghai Cancer Center (FUSCC), Shanghai, China. Eligible participants were females aged 18-70 years, with an Eastern Cooperative Oncology Group performance status of 0-1, and histologically confirmed, untreated metastatic or recurrent triple-negative breast cancer. After categorising participants into five cohorts according to molecular subtype and genomic biomarkers, participants were randomly assigned (1:1) with a block size of 4, stratified by subtype, to receive, in 28-day cycles, nab-paclitaxel (100 mg/m2, intravenously on days 1, 8, and 15) alone (control group) or with a subtyping-based regimen (subtyping-based group): pyrotinib (400 mg orally daily) for the LAR-HER2mut subtype, everolimus (10 mg orally daily) for the LAR-PI3K/AKTmut and MES-PI3K/AKTmut subtypes, camrelizumab (200 mg intravenously on days 1 and 15) and famitinib (20 mg orally daily) for the immunomodulatory subtype, and bevacizumab (10 mg/kg intravenously on days 1 and 15) for the BLIS/MES-PI3K/AKTWT subtype. The primary endpoint was investigator-assessed progression-free survival for the pooled subtyping-based group versus the control group in the intention-to-treat population (all randomly assigned participants). Safety was analysed in all patients with safety records who received at least one dose of study drug. This study is registered with ClinicalTrials.gov (NCT04395989). FINDINGS: Between July 28, 2020, and Oct 16, 2022, 139 female participants were enrolled and randomly assigned to the subtyping-based group (n=69) or control group (n=70). At the data cutoff (May 31, 2023), the median follow-up was 22·5 months (IQR 15·2-29·0). Median progression-free survival was significantly longer in the pooled subtyping-based group (11·3 months [95% CI 8·6-15·2]) than in the control group (5·8 months [4·0-6·7]; hazard ratio 0·44 [95% CI 0·30-0·65]; p<0·0001). The most common grade 3-4 treatment-related adverse events were neutropenia (21 [30%] of 69 in the pooled subtyping-based group vs 16 [23%] of 70 in the control group), anaemia (five [7%] vs none), and increased alanine aminotransferase (four [6%] vs one [1%]). Treatment-related serious adverse events were reported for seven (10%) of 69 patients in the subtyping-based group and none in the control group. No treatment-related deaths were reported in either group. INTERPRETATION: These findings highlight the potential clinical benefits of using molecular subtype-based treatment optimisation in patients with triple-negative breast cancer, suggesting a path for further clinical investigation. Phase 3 randomised clinical trials assessing the efficacy of subtyping-based regimens are now underway. FUNDING: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Shanghai Hospital Development Center, and Jiangsu Hengrui Pharmaceuticals. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fan L, Wang ZH, Ma LX, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024. PMID: 38211606. doi:10.1016/S1470-2045(23)00579-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。